Clinical Rheumatology最新文献

{"title":"Correlation between myocardial work and disease activity in rheumatoid arthritis patients with preserved left ventricular ejection fraction: a retrospective study based on non-invasive pressure-strain loop：.","authors":"Xiaolong Yu, Jing Xi, Jiabiao Wu, Ruixiao Song","doi":"10.1007/s10067-025-07380-5","DOIUrl":"https://doi.org/10.1007/s10067-025-07380-5","url":null,"abstract":"<p><strong>Background: </strong>Early cardiac damage is very common in RA patients, but it is usually subclinical. Therefore, finding a non-invasive method for the early detection and treatment of cardiac damage in autoimmune diseases is particularly important.diac dam RA ，。，。 OBJECTIVE: To evaluate left ventricular function changes in rheumatoid arthritis (RA) patients with preserved left ventricular ejection fraction (LVEF) using left ventricular pressure-strain loop (LV-PSL) technology and to explore the correlation between myocardial work (MW) and disease activity.- （LV-PSL） （LVEF） （RA） ， （MW） 。 METHODS: A total of 62 RA patients with preserved LVEF, treated at Wujin Hospital Affiliated with Jiangsu University from January 2021 to September 2023, were included. Patients were categorized into low (25), medium (18), and high (19) disease activity groups based on the 28 joint disease activity score (DAS28). A control group of 29 healthy individuals was also established. LV-PSL technology assessed left ventricular global longitudinal strain (GLS) and MW parameters: global constructive work (GCW), global wasted work (GWW), global work index (GWI), and global work efficiency (GWE). Correlations between MW parameters, GLS, LVEF, and DAS28 scores were analyzed. 2021 1 20239 62 LVEF RA 。 28 （DAS28） （25） 、 （18） （19） 。 29 。LV-PSL （GLS） MW ： （GCW）、 （GWW）、 （GWI） （GWE）。 MW 、 GLS 、 LVEF DAS28 。 RESULTS: There were no significant differences in general data between study and control groups (p > 0.05). However, laboratory indicators (RF, CRP, ESR) showed significant differences (p < 0.05). GWI, GCW, GWE, and GLS were significantly lower in the high disease activity group compared to controls (p < 0.05). GWI, GCW, and GWE were positively correlated with LVEF and absolute GLS, while GWW correlated negatively with LVEF (p < 0.05). （p > 0.05）。， （RF、CRP、ESR） （p < 0.05）。， GWI、GCW、GWE GLS （p < 0.05）。GWI、GCW GWE LVEF GLS ， GWW LVEF （p < 0.05）。 （p > 0.05）。， （RF、CRP、ESR） （p < 0.05）。， GWI、GCW、GWE GLS （p < 0.05）。GWI、GCW GWE LVEF GLS ， GWW LVEF （p < 0.05）。 CONCLUSION: RA disease activity is closely associated with impaired myocardial work. LV-PSL technology effectively monitors myocardial function abnormalities in RA patients, providing valuable insights for clinical management. Key Points • Myocardial work is significantly impaired in RA patients with high disease activity. • Left ventricular pressure-strain loop (LV-PSL) technology effectively assesses cardiac function in this patient population. • Increased disease activity correlates with reduced myocardial work parameters.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical value of salivary gland ultrasonography in evaluating secretory function, disease activity, and lymphoma risk factors in primary Sjögren's syndrome.","authors":"Jiwon Yang, Youngjae Park, Jennifer Jooha Lee, Wan-Uk Kim, Sung-Hwan Park, Seung-Ki Kwok","doi":"10.1007/s10067-025-07369-0","DOIUrl":"https://doi.org/10.1007/s10067-025-07369-0","url":null,"abstract":"<p><strong>Introduction/objectives: </strong>Salivary gland ultrasonography (SGUS) has been investigated for its diagnostic usefulness in replacing invasive minor salivary gland biopsy (MSGB) in primary Sjögren's syndrome (pSS). However, its broader clinical value remains unclear. This study aimed to assess the clinical significance of SGUS in evaluating secretory function, disease activity, and lymphoma risk factors in pSS.</p><p><strong>Method: </strong>One hundred fifty pSS patients who visited Seoul St. Mary's Hospital between January 2019 and July 2023 were included. Parameters related to secretory function, disease activity, and lymphoma risk factors were obtained. Associations between SGUS grades and secretory function or disease activity parameters were determined. Subgroup analyses based on SGUS grade or the presence of lymphadenopathy (LAP) in SGUS were also performed.</p><p><strong>Results: </strong>SGUS grades correlated significantly with parameters of salivary gland secretory function and disease activity. Higher SGUS grades were associated with higher scores of overall EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), ESSDAI glandular domain, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) dryness domain, and physician or patient global assessment. Patients with the highest SGUS grade (overall score = 6) showed higher prevalence of laboratory risk factors or extraglandular manifestations related to lymphoma development than others. Detection of LAP by SGUS was associated with reduced salivary flow rates and higher ESSDAI, ESSPRI scores, and patient global assessments.</p><p><strong>Conclusions: </strong>Our results suggest that SGUS grades and the presence of LAP in SGUS findings are associated with clinical parameters representing secretory function and disease activity in pSS. High SGUS grades are associated with risk factors for lymphoma development. Key Points • SGUS grades showed significant correlations with clinical parameters related to salivary gland function and disease activity in patients with pSS. • pSS patients with the highest SGUS grade exhibited a higher prevalence of laboratory risk factors or extraglandular manifestations potentially related to lymphoma development compared to others. • These associations were more pronounced in the parotid gland than in the submandibular gland. • LAP identified by SGUS showed significant associations with clinical parameters related to the quality of life of patients with pSS.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type D personality and social inhibition: drivers of cardiovascular risk and reduced physical activity in psoriatic arthritis.","authors":"Ayşegül Yetişir, Aylin Sariyildiz, Ilke Coskun Benlidayi, Süleyman Özbek","doi":"10.1007/s10067-025-07312-3","DOIUrl":"10.1007/s10067-025-07312-3","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the presence of type D personality and its association with metabolic syndrome (MetS), cardiovascular disease risk, and level of exercise in patients with psoriatic arthritis (PsA).</p><p><strong>Material and method: </strong>This cross-sectional study included patients with PsA (n = 84) and healthy controls (n = 74). Sociodemographic data, laboratory parameters, and disease-related parameters were recorded. We evaluated the presence of type D personality with the total 14 items of the type D Personality Scale, the Framingham Risk Score (FRS) indicating 10-year cardiovascular disease risk as low, moderate, and high, the presence of MetS, and physical activity levels by the International Physical Activity Questionnaire-Short Form (IPAQ-SF).</p><p><strong>Results: </strong>The median age of patients with PsA was 53.5 (17) years, 73.8% were female, and the disease duration was 7 (12) years. Compared to controls, patients with PsA exhibited higher FRS and increased frequency of MetS, type D personality, and its domains (social inhibition and negative affectivity) (p < 0.05 for all). Patients with type D personality had even a higher frequency of MetS and lower levels of moderate-intensity exercise than those without type D personality (p = 0.020 and p = 0.027). Patients with social inhibition had higher FRS, a higher frequency of MetS, and lower levels of moderate-intensity exercise (p < 0.05 for all) compared to those without social inhibition. MetS showed a significant positive correlation with social inhibition, waist circumference, and FRS (Spearman's rho were 0.244, 0.444, and 0.555, respectively), and a negative correlation with IPAQ-SF total metabolic equivalent (Spearman's rho was -0.214).</p><p><strong>Conclusion: </strong>Patients with type D personality and social inhibition had a higher frequency of MetS and low levels of moderate-intensity exercise, whereas patients with social inhibition had a higher FRS. It is essential to assess PsA patients' cardiac risk factors, type D personality, and social inhibition, as well as provide exercise advice. Key Points •Psoriatic arthritis (PsA) is a prevelant rheumatologic disease that is frequently accompanied by comorbidities such as metabolic syndrome (MetS) and cardiovascular disease (CVD). •It is crucial to evaluate patients with PsA for CVD risk factors. •Patients with type D personality demonstrate lower engagement in moderate-intensity exercise and a higher frequency of MetS. Socially inhibited PsA patients showed elevated Framingham Risk Scores and MetS rates, as well as reduced levels of moderate-intensity exercise. •Beyond assessing cardiac risk factors, it is important to assess personality traits and offer tailored exercise recommendations for comprehensive PsA management.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"1163-1171"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal metabolomic analysis of the role of gut microbiota and short-chain fatty acids in the therapeutic mechanism of Timosaponin AIII in Sjögren's syndrome.","authors":"Fengtao Pang, Quan Jiang, Xiaopo Tang, Kesong Li","doi":"10.1007/s10067-024-07294-8","DOIUrl":"10.1007/s10067-024-07294-8","url":null,"abstract":"<p><strong>Introduction/objectives: </strong>Sjogren's syndrome (SS) is a chronic inflammatory and difficult-to-treat autoimmune disease. Timosaponin AIII (TAIII), a plant-derived steroidal saponin, effectively inhibits cell proliferation, induces apoptosis, and exhibits anti-inflammatory properties. This study explored the mechanisms of action of TAIII in SS treatment by studying gut microbiota and short-chain fatty acids (SCFAs) using fecal metabolomics.</p><p><strong>Methods: </strong>The model group used non-obese diabetic (NOD) mice. The treatment group was classified into TAIII and hydroxychloroquine groups. The gut microbiota, SCFAs, and metabolites were analyzed using 16S rRNA sequencing, gas chromatography-mass spectrometry analysis, and liquid chromatography-mass spectrometry, respectively.</p><p><strong>Results: </strong>TAIII effectively alleviated dry mouth in NOD mice, slowed the progression of salivary gland tissue injury, reduced inflammatory factor expression, and increased the levels of aquaporins 1 and 5. TAIII regulated SCFA content and tryptophan metabolism by altering the abundance of the Rikenellaceae_RC9_gut_group, thereby reducing the inflammatory response. TAIII can improve imbalances in the gut microbiota and the metabolic levels of related SCFAs and tryptophan, thereby reducing the level of inflammation.</p><p><strong>Conclusion: </strong>The significant differences observed in the abundance of the Rikenellaceae_RC9_gut_group between the treatment and control groups indicated the potential relationship between bacteria and metabolites in SS. Key Points • The safe and effective treatment of SS with traditional Chinese medicine • Multi-means study on intestinal flora, short-chain fatty acids, and metabonomics.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"1209-1223"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary cryofibrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study.","authors":"Gilda Sandri, Gabriele Amati, Amelia Spinella, Patrizia Natali, Daria Debbia, Martina Orlandi, Ottavio Secchi, Benedetta Bongiovanni, Marco de Pinto, Maria Teresa Mascia, Dilia Giuggioli","doi":"10.1007/s10067-025-07324-z","DOIUrl":"10.1007/s10067-025-07324-z","url":null,"abstract":"&lt;p&gt;&lt;p&gt;The aims of this study were to investigate the prevalence of cryofibrinogenemia in a cohort of patients with systemic sclerosis (SSc) regardless of clinical manifestations, who were admitted to our hospital and determine the associations among CF positivity, disease features and ongoing therapies. This was a monocentric and retrospective study. The inclusion criteria were a diagnosis of SSc (according to the ACR/EULAR 2013 classification criteria), regular administration of i.v. prostanoids, and CF testing between February 2020 and February 2022. Data on demographic, clinical, and immunological features and ongoing treatments were retrospectively collected. Categorical data were compared with the chi-square test or Fisher's exact test, while quantitative variables comparisons were carried out with Student's t test or Mann‒Whitney test. In total, 101 SSc patients were ultimately enrolled. The majority of patients were female (92.1%) and had the limited cutaneous form of SSc (81.2%). CF positivity was observed in 69.3% of the patients, whereas only 9% presented cryoglobulins and CF. CF positivity was negatively associated to RNAP3 antibodies (p = 0.027). No direct associations with specific clinical phenotypes were observed. No associations with immunosuppressive treatments were identified, however a positive association with nifedipine administration (p = 0.040), and a negative association with endothelin receptor antagonists (ERAs) plus phosphodiesterase-5 (PDE5) inhibitors regimen (p = 0.031) were observed. Macitentan administration was also associated to CF cryocrit ≥ 1% (p = 0.045). Among patients who were not treated with ERAs, an estimated pulmonary artery systolic pressure ≥ 30 mmHg was significantly associated with CF positivity (p = 0.025). Moreover, a cryocrit ≥3% was associated with a relative risk of 3.44 (95% CI 1.26-9.39, p = 0.016) for digital amputation and 5.17 (95% CI 1.18-22.6, p = 0.029) for death. Isolated CF is a frequent phenomenon observed in SSc patients and is associated with a higher administration of vasoactive drugs, probably identifying a SSc clinical phenotype with a more severe microvascular involvement. Moreover, a higher cryocrit is associated with an increased risk of death and digital amputations. Screening SSc patients for CF would represent an opportunity to provide better therapeutic approaches by anticipating ERA administration in an earlier phase, thereby preventing the manifestation of severe microvascular involvement. Key Points • Cryofibrinogen is a cryoprotein that can cause microangiopathic damage. • Isolated cryofibrinogenemia is common in patients with systemic sclerosis. • SSc patients should be tested for cryofibrinogen because a high cryocrit (≥ 3%) is associated with death and/or digital amputation due to necrosis. • Cryofibrinogen is associated with indirect markers of pulmonary arterial hypertension in patients not treated with endothelin receptor agonists (ERAs). • ERAs could play a role","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"1173-1185"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a prediction model for serious infections in rheumatoid arthritis patients treated with tocilizumab in Japan.","authors":"Toshihiro Nanki, Tomohiro Yamaguchi, Kosei Umetsu, Ryunosuke Tanabe, Naoki Maeda, Minori Kanazawa, Yuko Furuno, Shinichi Matsuda, Shinya Takemoto, Keiko Asao, Tatsuya Kamiuchi","doi":"10.1007/s10067-025-07328-9","DOIUrl":"10.1007/s10067-025-07328-9","url":null,"abstract":"<p><strong>Objectives: </strong>To develop a prediction model for serious infections (SIs) in rheumatoid arthritis (RA) patients treated with tocilizumab in Japan and to evaluate the model's performance compared to previously developed models, i.e., 'DANBIO' and 'postmarketing surveillance' (PMS).</p><p><strong>Method: </strong>This non-interventional retrospective cohort study utilized the Medical Data Vision database in Japan. The study population was derived from patients ≥ 18 years with RA who initiated tocilizumab between April 2008 and July 2021. SIs were assessed during the 1-year follow-up from tocilizumab initiation. The candidate predictors were identified based on previous studies, known risk factors, potentially relevant factors, and data availability. The prediction model was developed using logistic regression. The model's performance was compared with previously developed models using cross-entropy and area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Of the 6501 RA patients, 4.57% experienced SIs during the 1-year follow-up. The model included 17 predictors for SI (e.g., age (odds ratio 1.013 (95% confidence interval 1.002-1.024)), history of SIs (2.569 (1.636-3.745)), diverticulitis (2.183 (1.000-3.989))). The model showed a lower cross-entropy and a higher AUC (0.1488; 0.712) compared to DANBIO (0.1932; 0.591) and PMS (0.1561; 0.565) models, and the sensitivity, specificity, positive predictive value, and negative predictive value using 5% threshold were 72%, 64%, 7%, and 98%, respectively.</p><p><strong>Conclusions: </strong>The model developed in this study seems to have the potential to inform the risk of SIs in RA patients treated with tocilizumab and may help the early identification of patients at risk of SIs to reduce morbidity and mortality.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"1081-1093"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediating effect of X-26109 on the causal relationship between CD14⁺ CD16^- monocyte activation complex and rheumatoid arthritis in Europe.","authors":"Han Wang, Jinjie Chu, Yan Wang, Yongqin Wu, Wenchao Zhou","doi":"10.1007/s10067-025-07300-7","DOIUrl":"10.1007/s10067-025-07300-7","url":null,"abstract":"<p><p>The regulation of the immune system is crucial in the pathogenesis of various diseases. The direct involvement of immune cells in the development of rheumatoid arthritis (RA) and the potential mediation by metabolites remains to be elucidated. This study utilized a two-step, two-sample Mendelian randomization (MR) approach employing the inverse variance weighted (IVW) method to investigate the causal role of immune cells in RA and to assess the mediation effect of metabolites on the association between immune cells and RA. MR analyses identified 44 immune cell traits that were suggestively associated with RA. Additionally, five metabolites demonstrated protective effects against RA. Notably, mediation MR indicated that the causal role of CD14⁺ CD16^- monocyte activation complex (AC) on RA (total effect IVW: OR = 0.978, 95% CI [0.959, 0.998], P = 0.028) was significantly mediated by X-26109 levels, accounting for 7.32% of the total effect. This study provides evidence of a causal relationship between immune cells and RA, with metabolites potentially mediating this relationship. Key Points • Mendelian randomization (MR) analysis was used to investigate the causal impact of immune cells on RA progression and the potential mediating role of metabolites, identifying 44 immune cell traits and several metabolites associated with RA risk • The study found that CD14 + CD16 - monocyte activation complex (AC) is associated with a reduced RA risk, with this effect largely mediated by metabolite X-26109 levels, suggesting a potential therapeutic target for RA prevention and treatment.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"1095-1102"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study.","authors":"Fang Fang, Hongmei Duan, Shuang Ding","doi":"10.1007/s10067-025-07348-5","DOIUrl":"10.1007/s10067-025-07348-5","url":null,"abstract":"<p><strong>Introduction /objectives: </strong>Telitacicept provides a promising therapeutic option for systemic lupus erythematosus (SLE). This study aims to evaluate the real-world effectiveness and safety of telitacicept in Chinese patients with SLE.</p><p><strong>Methods: </strong>This retrospective study included 38 SLE patients treated with telitacicept for at least six months. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment (PGA), British Isles Lupus Assessment Group (BILAG) index, and the Systemic Lupus Erythematosus Responder Index 4 (SRI-4).</p><p><strong>Results: </strong>Telitacicept significantly reduced SLEDAI score from a median of 8.50 (interquartile range [IQR] 6.25-12.00) at baseline to 2.00 (IQR 0.00-4.00) at six months (p<0.001). At three months, 65.8% of patients achieved a ≥4-point reduction in SLEDAI scores, which increased to 81.6% at six months. PGA scores decreased from a median of 1.80 (IQR 1.60-2.60) at baseline to 0.90 (IQR 0.60-1.30) at six months (p<0.001). BILAG scores improved from a median of 4.00 (IQR 4.00-9.00) at baseline to 0.00 (IQR 0.00-1.00) at six months (p<0.001). The SRI-4 response rates were 65.8% at three months and 78.9% at six months. Concomitant glucocorticoid use decreased notably, with 41.2% of patients experiencing a dose reduction of at least 25%, and 38.2% experiencing glucocorticoid discontinuation altogether. The reported AEs were mild, including injection site reactions and mild diarrhea.</p><p><strong>Conclusions: </strong>This real-world study indicates that telitacicept is effective and well-tolerated in the management of SLE, with substantial improvements in disease activity and reductions in glucocorticoid and immunosuppressant use.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"1113-1122"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features of inflammatory arthritis in daily practice-China's perspective.","authors":"Wenwen Pei, Liling Xu, Hua Zhong, Ziye Wang, Ranran Yao, Lei Zhang, Jing Yang, Jingyang Li, Yuan Feng, Qi Lin, Dongsheng Li, Xinyao Zhou, Dongxue Pei, Yanqiu Guo, Li Ma, Yaping Luo, Shufei Zuo, Lin Wang, Rui Yan, Yin Su","doi":"10.1007/s10067-024-07262-2","DOIUrl":"10.1007/s10067-024-07262-2","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to analyze and compare the proportion of patients with different types of inflammatory arthritis and investigate the clinical characteristics, including symptoms and signs, medication choices, and disease activity, in the daily clinical practice of China.</p><p><strong>Methods: </strong>Patients with inflammatory arthritis were recruited from 16 Grade-A tertiary hospitals between August 2021 and April 2022. The medical profiles, encompassing sociodemographic characteristics, clinical and laboratory date, were collected.</p><p><strong>Results: </strong>This study included 2,693 patients with arthritis, with rheumatoid arthritis (RA) accounting for the highest proportion (50.50%). Significant differences were observed in terms of age, gender, body mass index (BMI), disease duration, smoking and family history among patients with different types of inflammatory arthritis. Physical activity and cold exposure were identified as the main predisposing factors for RA, psoriatic arthritis (PsA), osteoarthritis (OA), and ankylosing spondylitis (AS), while alcohol consumption was the most common inducing factor for gout. Hypertension and hyperlipidemia were the primary concomitant diseases in RA, OA, and AS, whereas hyperuricemia and hypertension were mainly associated with gout, psoriasis and diabetes were the most common comorbidities in PsA. Peripheral joints were predominantly affected in PsA, RA, OA, and gout, while axial joints were mainly affected in AS. Methotrexate and leflunomide were the main therapeutic drugs for RA, while biologics were commonly prescribed for PsA and AS. OA and gout patients mainly utilized nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p><strong>Conclusion: </strong>Patients with different types of inflammatory arthritis exhibited varying predisposing factors, joint inflammation, concomitant diseases, and medication choices, highlighting the importance of individualized approaches in the clinic. Key Points • 2,693 patients classified and diagnosed with inflammatory arthritis were recruited in this study from 16 Grade-A tertiary hospitals in China between August 2021 and April 2022. • This study analyzed and compared the proportion of patients with different types of arthritis in routine clinical practice in China. • Joint inflammation, comorbidities, and medication choices were assessed among patients with the most common types of arthritis in this study. • This study also provided some epidemiologically relevant information about inflammatory arthritis patients in China.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"969-978"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease masquerading as rheumatoid arthritis-associated interstitial lung disease or overlapping with the same: a phenomenon driven by a probable genetic predisposition.","authors":"Abraham Mohan, Aiswarya Mohan, Anuradha Ramachandran, Jacob George Pulinilkunnathil, Deepu M","doi":"10.1007/s10067-025-07351-w","DOIUrl":"10.1007/s10067-025-07351-w","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a systemic, progressive illness marked by persistent synovitis that causes substantial functional disability. Treatment delays frequently affect health-related quality of life. Extra-articular features are prevalent findings in RA, which leads to significant morbidity and mortality. They are likely due to chronic inflammation and autoimmune nature of RA. Extra-articular manifestations also include interstitial lung disease (ILD). Anti-MDA5 antibodies, though typically associated with dermatomyositis, may also occur with RA, especially in patients with overlapping syndromes, and influence ILD severity. In this case-based review, we highlight the challenges in managing a case of seropositive RA complicated by the coexistence of anti-MDA5 antibody. This review additionally examines the pathophysiology, clinical presentation, diagnosis, therapy, and prognosis of RA-ILD along with that of anti-MDA-5ILD, as well as new studies and recommendations for disease management.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"1367-1375"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}